With venetoclax/ABT-199, the first of these BH3-mimetics targeting Bcl-2 has been approved for the treatment of leukemia, highlighting the potential of the Bcl-2 proteins as targets in anticancer therapy [41]. Here, BCL2 is linked to leukemia.